ZTSZoetis Inc.

Ticker: ZTS | Filing Type: 8-K (Items 2.02, 9.01) | Filed with the SEC on: November 5, 2026 Current Price: $79.69 | Today's Change: -2.95%

---

What Happened

Zoetis Inc. filed an 8-K with the SEC on November 5, 2026, disclosing its financial results for Q3 FY2026 under Item 2.02 (Results of Operations and Financial Condition). The company reported revenues of $7.094 billion and net income of $2.049 billion for the quarter. Both basic and diluted earnings per share came in at $4.60, reflecting a solid per-share earnings profile for the period.

Why It Matters

For investors, the headline numbers represent a snapshot of Zoetis's ability to generate revenue and profit from its animal health portfolio. Net income of over $2 billion on roughly $7.1 billion in revenue translates to a net margin of approximately 28.9%, underscoring the company's ability to convert top-line sales into bottom-line profit. The stock's decline of -2.95% on the day of this report suggests the market may have had higher expectations going into the print, or that broader market conditions are weighing on the share price — though the precise cause of the move is not stated in the filing itself. Investors should note that the per-share earnings figure of $4.60 (both basic and diluted being identical) indicates minimal dilution from equity-based compensation or convertible instruments during the quarter.

Analysis

The near-identical basic and diluted EPS figure of $4.60 is a subtle positive signal — it suggests Zoetis's share count is well-managed, with limited dilutive pressure. The revenue figure of $7.094 billion on a nine-month cumulative basis (noted as Q3 FY2026 in the XBRL data) warrants clarification: if this represents year-to-date revenues rather than a single quarter, the per-quarter run rate would be considerably lower, and analysts and investors should consult the full filing and income statement footnotes to confirm the exact measurement period.

The key items to watch going forward include:

• Revenue trajectory: Whether growth is being driven by companion animal products (historically a high-margin segment) or the livestock segment, which tends to be more cyclical.
• Margin sustainability: A ~29% net margin is strong for a pharmaceutical/biotech-adjacent company, but input costs, R&D spend, and pricing pressure in key markets bear monitoring.
• Capital allocation: Given the scale of net income, how Zoetis deploys cash — whether through buybacks, dividends, or M&A — will be a focal point for the market.
• Share price reaction: The -2.95% move warrants attention; if results met or exceeded internal guidance, management commentary from the accompanying earnings call will be critical context.

Investors are encouraged to review the full filing and any accompanying press releases or earnings call transcripts for complete context.

Disclaimer

This report is provided for informational and news purposes only. It is based solely on data contained in Zoetis Inc.'s SEC filing dated November 5, 2026, and does not constitute investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. No investment rating or price target is expressed or implied. Past financial results are not necessarily indicative of future performance. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1555280/000155528026000048/zts-20261105.htm